These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 38411622)

  • 1. Combined Protection of Vaccination and Nirmatrelvir-Ritonavir Against Hospitalization in Adults With COVID-19.
    Shah MM; Joyce B; Plumb ID; Sahakian S; Feldstein LR; Barkley E; Paccione M; Deckert J; Sandmann D; Hagen MB; Gerhart JL
    Clin Infect Dis; 2024 Jul; 79(1):108-110. PubMed ID: 38411622
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19.
    Hammond J; Leister-Tebbe H; Gardner A; Abreu P; Bao W; Wisemandle W; Baniecki M; Hendrick VM; Damle B; Simón-Campos A; Pypstra R; Rusnak JM;
    N Engl J Med; 2022 Apr; 386(15):1397-1408. PubMed ID: 35172054
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparing the effectiveness of molnupiravir and nirmatrelvir-ritonavir in non-hospitalized and hospitalized COVID-19 patients with type 2 diabetes: A target trial emulation study.
    Wan EYF; Wong ZCT; Yan VKC; Chui CSL; Lai FTT; Li X; Wong ICK; Chan EWY
    Diabetes Obes Metab; 2024 Oct; 26(10):4653-4664. PubMed ID: 39109461
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Molnupiravir or nirmatrelvir-ritonavir reduce the likelihood of hospitalization and mortality in immunocompromised patients with Covid-19.].
    Kurotschka PK; Ebell MH; Serafini A
    Recenti Prog Med; 2024 Sep; 115(9):399. PubMed ID: 39269352
    [No Abstract]   [Full Text] [Related]  

  • 5. COVID-19 hospitalization risk after outpatient nirmatrelvir/ritonavir use, January to August 2022, North Carolina.
    Henderson HI; Wohl DA; Fischer WA; Bartelt LA; van Duin D; Agil DM; Browne LE; Li KP; Moy A; Eron JJ; Napravnik S
    J Antimicrob Chemother; 2024 Apr; 79(4):859-867. PubMed ID: 38380946
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral Nirmatrelvir-Ritonavir as Postexposure Prophylaxis for Covid-19.
    Hammond J; Yunis C; Fountaine RJ; Luscan G; Burr AM; Zhang W; Wisemandle W; Soares H; Baniecki ML; Hendrick VM; Kalfov V; Pypstra R; Rusnak JM
    N Engl J Med; 2024 Jul; 391(3):224-234. PubMed ID: 39018532
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of effectiveness and safety of nirmatrelvir/ritonavir versus sotrovimab for COVID-19: a systematic review and meta-analysis.
    Amani B; Amani B
    Expert Rev Anti Infect Ther; 2024 Jul; 22(7):547-555. PubMed ID: 38457124
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nirmatrelvir/ritonavir use in pregnant women with SARS-CoV-2 Omicron infection: a target trial emulation.
    Wong CKH; Lau KTK; Chung MSH; Au ICH; Cheung KW; Lau EHY; Daoud Y; Cowling BJ; Leung GM
    Nat Med; 2024 Jan; 30(1):112-116. PubMed ID: 37913816
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Delayed treatment with nirmatrelvir/ritonavir could remain effective in patients with Omicron BA2.2 variant of COVID-19.
    Wang W; Wan J; Du W; Song J; Lu Y; Gu S; Feng Y; Wang G; Tao M; Yin J
    Ann Acad Med Singap; 2023 Mar; 52(3):158-160. PubMed ID: 38904494
    [No Abstract]   [Full Text] [Related]  

  • 10. Early administration of nirmatrelvir/ritonavir leads to faster negative SARS-CoV-2 nasal swabs than monoclonal antibodies in COVID 19 patients at high-risk for severe disease.
    Colaneri M; Scaglione G; Fassio F; Galli L; Lai A; Bergna A; Gabrieli A; Tarkowski M; Ventura CD; Colombo V; Cordier L; Bernasconi D; Corbellino M; Dedivitiis G; Borghetti S; Visigalli D; Sollima S; Casalini G; Rizzardini G; Gori A; Antinori S; Riva A; Schiavini M
    Virol J; 2024 Mar; 21(1):68. PubMed ID: 38509536
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of nirmatrelvir/ritonavir and molnupiravir in non-hospitalized adults with COVID-19: systematic review and meta-analysis of observational studies.
    Mesfin YM; Blais JE; Kibret KT; Tegegne TK; Cowling BJ; Wu P
    J Antimicrob Chemother; 2024 Sep; 79(9):2119-2131. PubMed ID: 38817046
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characteristics and Outcomes of US Veterans With Immunocompromised Conditions at High Risk of SARS-CoV-2 Infection With or Without Receipt of Oral Antiviral Agents.
    Gentry CA; Nguyen PN; Thind SK; Kurdgelashvili G; Williams RJ
    Clin Infect Dis; 2024 Feb; 78(2):330-337. PubMed ID: 37619991
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of nirmatrelvir-ritonavir on severe outcomes of COVID-19 in the era of vaccination and Omicron: An updated meta-analysis.
    Ombelet S; Castanares-Zapatero D; Desimpel F; Hulstaert F; Stordeur S; Roberfroid D
    J Med Virol; 2024 Feb; 96(2):e29434. PubMed ID: 38376947
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nirmatrelvir/ritonavir or Molnupiravir for treatment of non-hospitalized patients with COVID-19 at risk of disease progression.
    Butt AA; Yan P; Shaikh OS
    PLoS One; 2024; 19(6):e0298254. PubMed ID: 38843201
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral Nirmatrelvir-Ritonavir Use and Clinical Outcomes in Pregnant Patients With Coronavirus Disease 2019 (COVID-19).
    Toure BB; Panakam A; Johns SL; Butler SK; Tuomala RE; Diouf K
    Obstet Gynecol; 2024 Feb; 143(2):273-276. PubMed ID: 37963387
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A National Strategy for COVID-19 Medical Countermeasures: Vaccines and Therapeutics.
    Borio LL; Bright RA; Emanuel EJ
    JAMA; 2022 Jan; 327(3):215-216. PubMed ID: 34989782
    [No Abstract]   [Full Text] [Related]  

  • 17. Predictors of nirmatrelvir-ritonavir receipt among COVID-19 patients in a large US health system.
    Malden DE; McLaughlin JM; Hong V; Lewnard J; Ackerson BK; Puzniak L; Kim JS; Takhar H; Frankland TB; Slezak JM; Tartof SY
    Sci Rep; 2024 Mar; 14(1):7485. PubMed ID: 38553527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-Life Comparison of Antivirals for SARS-CoV-2 Omicron Infection in Patients With Hematologic Malignancies.
    Aiello TF; Peyrony O; Chumbita M; Monzó P; Lopera C; Puerta-Alcalde P; Magnano L; Fernández-Avilés F; Cuesta G; Tuset M; Mensa J; Esteve J; Marcos MA; Soriano A; Garcia-Vidal C
    Influenza Other Respir Viruses; 2024; 18(3):e13264. PubMed ID: 38468434
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early use of oral antiviral drugs and the risk of post COVID-19 syndrome: A systematic review and network meta-analysis.
    Jiang J; Li Y; Jiang Q; Jiang Y; Qin H; Li Y
    J Infect; 2024 Aug; 89(2):106190. PubMed ID: 38834107
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Joint analysis of vaccination effectiveness and antiviral drug effectiveness for COVID-19: a causal inference approach.
    Cheung YYH; Lau EHY; Yin G; Lin Y; Jiang J; Cowling BJ; Lam KF
    Int J Infect Dis; 2024 Jun; 143():107012. PubMed ID: 38521448
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.